Evaluation of Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Using MRI-Based Remission Criteria: A Prospective, Single-Arm, Multicenter Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07872449

Title field or adapter rule

{'original_value': "Evaluation of Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Using MRI-Based Remission Criteria: A Prospective, Single-Arm, Multicenter Study", 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:36.333874+00:00

Published At

2026-10-23T00:00:00+00:00

Record Updated At

2026-10-23

Source Retrieved At

2026-10-31T22:18:56.524747+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Crohn Disease", "Perianal Fistula", "Perianal Fistula Due to Crohn\u0027s Disease", "Perianal Crohn\u0027s Disease"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-23", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07872449"

protocolSection.identificationModule.officialTitle

"Evaluation of Risankizumab for Refractory Perianal Fistulizing Crohn\u0027s Disease Using MRI-Based Remission Criteria: A Prospective, Single-Arm, Multicenter Study"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE4"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Crohn Disease (protocolSection.conditionsModule.conditions)
• Perianal Fistula (protocolSection.conditionsModule.conditions)
• Perianal Fistula Due to Crohn's Disease (protocolSection.conditionsModule.conditions)
• Perianal Crohn's Disease (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Risankizumab Treatment Arm'], 'description': "Risankizumab (Skyrizi®, AbbVie Inc.) is a humanized IgG1 monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23). For Crohn's disease, participants receive 600 mg intravenously (IV) at Weeks 0, 4, and 8 as induction therapy, followed by 360 mg subcutaneously (SC) at Week 12 and every 8 weeks thereafter as maintenance therapy. If efficacy diminishes 16 weeks or later after initiating maintenance therapy with the subcutaneous formulation of risankizumab, a single intravenous infusion of 1200 mg may be administered (rescue therapy).", 'name': 'Risankizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Risankizumab (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.